Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)

被引：0

作者：

Cheng, A. -L. ^{[1
]}

Finn, R. S. ^{[2
]}

Qin, S. ^{[3
]}

Han, K. -H. ^{[4
]}

Ikeda, K. ^{[5
]}

Piscaglia, F. ^{[6
]}

Baron, A. ^{[7
]}

Park, J. -W. ^{[8
]}

Han, G. ^{[9
]}

Jassem, J. ^{[10
]}

Blanc, J. F. ^{[11
]}

Vogel, A. ^{[12
]}

Komov, D. ^{[13
]}

Evans, T. J. ^{[14
]}

Lopez, C. ^{[15
]}

Dutcus, C. ^{[16
]}

Ren, M. ^{[16
]}

Kraljevic, S. ^{[17
]}

Tamai, T. ^{[16
]}

Kudo, M. ^{[18
]}

机构：

[1] Natl Taiwan Univ Hosp, Taipei, Taiwan

[2] UCLA Med Ctr, Geffen Sch Med, Santa Monica, CA USA

[3] Nanjing Bayi Hosp, Nanjing, Jiangsu, Peoples R China

[4] Yonsei Univ, Severance Hosp, Seoul, South Korea

[5] Toranomon Gen Hosp, Tokyo, Japan

[6] Univ Bologna, Bologna, Italy

[7] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA

[8] Natl Canc Ctr Korea, Goyang Si, South Korea

[9] Fourth Mil Med Univ, Xijing Hosp, Xian, Shaanxi, Peoples R China

[10] Med Univ Gdansk, Gdansk, Poland

[11] Univ Bordeaux, Bordeaux, France

[12] Hannover Med Sch, Hannover, Germany

[13] NN Blokhin Canc Res Ctr, Moscow, Russia

[14] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[15] Marques de Valdecilla Univ Hosp, Santander, Spain

[16] Eisai Inc, Woodcliff Lake, NJ USA

[17] Eisai Ltd, Hatfield, PA USA

[18] Kindai Univ, Fac Med, Osaka, Japan

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

'V720

引用

页码：211 / 211

页数：1

共 50 条

[21] An Indirect Treatment Comparison of Lenvatinib for the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma
Ndirangu, Kerigo
Paine, Abby
Pilkington, Hollie
Trueman, David
ADVANCES IN THERAPY, 2025, 42 (02) : 977 - 994
[22] A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).
Zhu, Andrew X.
Finn, Richard S.
Ikeda, Masafumi
Sung, Max W.
Baron, Ari David
Kudo, Masatoshi
Okusaka, Takuji
Kobayashi, Masahiro
Kumada, Hiromitsu
Kaneko, Shuichi
Pracht, Marc
Mamontov, Konstantin
Meyer, Tim
Mody, Kalgi
Kubota, Tomoki
Dutcus, Corina E.
Saito, Kenichi
Siegel, Abby B.
Dubrovsky, Leonid
Llovet, Josep M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[23] Lenvatinib (L) and sorafenib (S) in patients (pts) with advanced or unresectable hepatocellular carcinoma (uHCC): An international, multicenter, phase IV study (STELLAR)
Radosavljevic, M. Peck
Abdelgafur, A. M.
Granito, A.
Gasbarrini, A.
Ma, Y.
Mena, E.
Lledo-Navarro, J. L.
Presa, J.
Weinmann, A.
Levy, M. T.
Pellicelli, A.
Waldschmidt, D. T.
Sorensen, H. T.
Goyal, L.
Ren, M.
Saal, H.
Okpara, C. E.
Meyer, T.
ANNALS OF ONCOLOGY, 2024, 35 : S664 - S664
[24] Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC)
Alsina, Angel
Kudo, Masatoshi
Vogel, Arndt
Cheng, Ann-Lii
Tak, Won Young
Ryoo, Baek-Yeol
Evans, T. R. Jeffry
Lopez, Carlos Lopez
Daniele, Bruno
Blanc, Jean-Frederic
Ren, Min
Baldwin, Rae Lynn
Izumi, Namiki
Qin, Shukui
Finn, Richard S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[25] Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
Qin, S.
Chan, L. S.
Gu, S.
Bai, Y.
Ren, Z.
Lin, X.
Chen, Z.
Jia, W.
Jin, Y.
Guo, Y.
Sultanbaev, A. V.
Pazgan-Simon, M.
Pisetska, M.
Liang, X.
Chen, C.
Nie, Z.
Wang, L.
Cheng, A-L.
Kaseb, A.
Vogel, A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1401 - S1402
[26] Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis
Kim, John J.
McFarlane, Thomas
Tully, Stephen
Wong, William W. L.
ONCOLOGIST, 2020, 25 (03): : E512 - E519
[27] Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis
Casadei-Gardini, Andrea
Scartozzi, Mario
Tada, Toshifumi
Yoo, Changhoon
Shimose, Shigeo
Masi, Gianluca
Lonardi, Sara
Frassineti, Luca Giovanni
Nicola, Silvestris
Piscaglia, Fabio
Kumada, Takashi
Kim, Hyung-Don
Koga, Hironori
Vivaldi, Caterina
Solda, Caterina
Hiraoka, Atsushi
Bang, Yeonghak
Atsukawa, Masanori
Torimura, Takuji
Tsuj, Kunihiko
Itobayashi, Ei
Toyoda, Hidenori
Fukunishi, Shinya
Rimassa, Lorenza
Rimini, Margherita
Cascinu, Stefano
Cucchetti, Alessandro
LIVER INTERNATIONAL, 2021, 41 (06) : 1389 - 1397
[28] Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
Llovet, Josep M.
Kudo, Masatoshi
Cheng, Ann-Lii
Finn, Richard S.
Galle, Peter R.
Kaneko, Shuichi
Meyer, Tim
Qin, Shukui
Dutcus, Corina E.
Chen, Erluo
Dubrovsky, Leonid
Zhu, Andrew X.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[29] A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
Llovet, Josep
Finn, Richard
Ikeda, Masfumi
Sung, Max
Baron, Ari
Kudo, Masatoshi
Okusaka, Takuji
Kobayashi, Masahiro
Kumada, Hiromitsu
Kaneko, Suichi
Pracht, Marc
Mamontov, Konstantin
Meyer, Tim
Mody, Kalgi
Kubota, Tomoki
Dutcus, Corina
Saito, Kenichi
Siegel, Abby
Dubrovsky, Leonid
Young, Louise
Zhu, Andrew X.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 189 - 190
[30] Sorafenib and Lenvatinib as first-line treatment of hepatocellular carcinoma: A still controversial comparison
Beenet, Linda
LIVER INTERNATIONAL, 2021, 41 (06) : 1432 - 1432

← 1 2 3 4 5 →